GET DAILY SIGNALSCompugen (CGEN): Tracking Clinical Milestones in Ovarian Cancer Immunotherapy
Key Takeaways
- Key inflection point ahead: Compugen's wholly owned COM701 candidate is on track for an interim analysis with median progression-free survival (PFS) data in the MAIA-ovarian trial by the first quarter of 2027, a readout that could inform a registration path.
- Validated partnerships: AstraZeneca is advancing rilvegostomig across 11 Phase 3 trials, while Gilead is progressing GS-0321, together representing up to roughly $1 billion in potential milestone payments plus royalties.
- Strategic positioning: The company's AI/ML-powered Unigen discovery platform underpins a differentiated immuno-oncology pipeline and a "target discovery" engine that could generate future assets.
- Financial runway: Management has guided that cash and equivalents are expected to fund operations into 2029, reducing near-term dilution risk.
- Analyst stance: Consensus coverage is broadly constructive, with a "Strong Buy" profile and an average 12-month price target clustered in the $4.60 to $5.00 range against a low-to-high band of roughly $4.00 to $6.00.
- Key risks: Binary clinical-trial outcomes, dependence on partner execution, and the inherent volatility of small-cap biotech could materially alter the outlook.
- For additional context on this company's Major News, Today's Price Move, Price Targets, and Earnings, explore the dedicated Tickeron pages.
- Readers interested in AI-driven trading ideas can explore Trending AI Robots for additional market signals.
Strategic Positioning and Competitive Outlook
Compugen operates as a clinical-stage cancer immunotherapy company that sets itself apart by leaning on computational target discovery instead of traditional screening approaches alone. Its Unigen platform, driven by artificial intelligence and machine learning, has already pinpointed the targets for COM701, COM902, and GS-0321. This positions the company as both a drug developer and a potential ongoing source of new immuno-oncology candidates. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
The structure offers a de-risked model. Its most advanced partnered asset, rilvegostomig, is a bispecific antibody targeting PD-1 and TIGIT that AstraZeneca is moving through 11 Phase 3 programs. This setup allows Compugen to keep milestone and royalty economics while shifting late-stage costs to a major partner. The wholly owned lead program, COM701, targets PVRIG, a checkpoint pathway the company views as distinct from PD-1 and TIGIT, which could give it first-in-class potential in ovarian cancer maintenance therapy.
Major Catalysts Ahead
The main near-term catalyst remains the MAIA-ovarian interim analysis for COM701, expected in the first quarter of 2027. With no approved standard of care for relapsed platinum-sensitive ovarian cancer in the maintenance setting, a clear PFS benefit versus placebo could open a registration path and position COM701 as a potential combination backbone. Management has noted that a meaningful improvement over the roughly 5.5-month benchmark PFS in the control arm would stand out.
Additional catalysts include ongoing data from AstraZeneca’s rilvegostomig program at major oncology meetings and progress on the Gilead-partnered GS-0321 Phase 1 trial. Compugen’s next quarterly report, due in early November 2026, should offer updates on enrollment and timelines. On the analyst side, sentiment stays constructive, with consensus ratings described as “Strong Buy” and average 12-month price targets near $4.60 to $5.00, ranging from $4.00 to $6.00. New coverage initiations and reiterations in 2026 suggest stable sell-side conviction despite the binary clinical risk.
Industry and Macroeconomic Forces
As a clinical-stage biotech, Compugen’s path depends more on scientific and regulatory results than on standard economic cycles. Still, higher interest rates can indirectly pressure valuations for pre-revenue firms and affect partnership terms. Inflationary pressures on trial and manufacturing costs may influence cash burn, though the guided runway into 2029 offers a solid buffer. The broader immuno-oncology space continues to provide structural support through ongoing investment in checkpoint and bispecific therapies. Regulatory openness to new mechanisms in areas like ovarian cancer remains an important factor. While Compugen’s Israeli operations add some execution considerations, its ties with AstraZeneca and Gilead extend global development reach.
2026 Outlook and Long-Term Themes to Watch
Looking ahead to 2026 and beyond, the focus centers on whether Compugen can translate its differentiated biology into confirmed clinical data. The Q1 2027 COM701 interim readout stands as the pivotal event that could either support a registration strategy or prompt a review of the internal pipeline. Positive results would bolster the case for COM701 as a backbone therapy in ovarian cancer and potentially other settings. Longer term, the economics from rilvegostomig and GS-0321 carry weight comparable to the internal programs. AstraZeneca has previously projected non-risk-adjusted peak annual revenue potential above $5 billion for rilvegostomig, with Compugen eligible for milestones plus tiered royalties. The Unigen platform adds underappreciated optionality through future candidates that could lead to more partnerships. Capital allocation discipline will shape margins, and the extended cash runway points to a focus on non-dilutive financing. Competitive threats from other checkpoint and bispecific programs, along with regulatory shifts in oncology, will influence any registration path. Investors will monitor whether consensus expectations, currently reflected in price targets well above recent levels, remain steady as data catalysts near.
Exploring AI Tools for Stock Analysis
In my own research process, I frequently turn to Tickeron’s Trend Prediction Engine to evaluate potential price movements for stocks like CGEN. This AI-powered tool provides forecasts on whether an asset may trend bullish, bearish, or sideways over the coming weeks or months, helping to identify developing patterns alongside fundamental analysis. It offers searchable categories, historical context, and alerts that can complement clinical and partnership updates when assessing technical momentum.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
I’m a trader and independent researcher. My interest lies at the intersection of financial markets, algorithms, and capital management. I develop data-driven tools and strategies and study algorithmic approaches to market analysis. I help turn complex market data into clear insights and practical systems. I believe technology should support, not replace, investment thinking
CGEN's RSI Indicator ascends from oversold territory
The RSI Oscillator for CGEN moved out of oversold territory on October 20, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 44 similar instances when the indicator left oversold territory. In 39 of the 44 cases the stock moved higher. This puts the odds of a move higher at 89%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 51 of 66 cases where CGEN's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 77%.
The Moving Average Convergence Divergence (MACD) for CGEN just turned positive on October 28, 2026. Looking at past instances where CGEN's MACD turned positive, the stock continued to rise in 42 of 49 cases over the following month. The odds of a continued upward trend are 86%.
Following a +3.55% 3-day Advance, the price is estimated to grow further. Considering data from situations where CGEN advanced for three days, in 190 of 234 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
CGEN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 03, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CGEN as a result. In 73 of 83 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 88%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CGEN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
The Aroon Indicator for CGEN entered a downward trend on November 03, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is 20 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Seasonality Score of 42 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 56 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 63 (best 1 - 100 worst), indicating steady price growth. CGEN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.146) is normal, around the industry mean (3.051). P/E Ratio (5.289) is within average values for comparable stocks, (-0.872). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (125.677) among similar stocks. P/S Ratio (3.083) is also within normal values, averaging (439.647).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CGEN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a maker of drug and diagnostics
Industry Biotechnology
Advertisement